Medipure Announces MOU With Top Industrie to Establish Pharmaceutical Production Platform
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/05/15 -- Medipure Holdings Inc. ("Medipure," or the "Company") (CSE: MDH) is pleased to announce that it has entered into a Memorandum of Understanding ("MOU") with France''s Top Industrie to develop green technologies that will facilitate the implementation of Medipure''s operational production platform. The partnership created by this MOU will seek to advance Medipure''s scientific, technological, and production capacities. Implementation of Medipure''s operational production platform will be crucial for the progress of the Company''s R&D and pharmaceutical production activities.
Medipure''s research program has identified ''supercritical'' technology as the most viable, cost- effective, and eco-friendly option for the production of cannabinoids at industrial scales. As a result, the Company is currently focused on the in-house development of a supercritical fluid based infrastructure. Supercritical fluid technology uses carbon dioxide as an extraction and purification solvent, which is superior, non-flammable, and non-toxic, mitigating negative environmental impacts as well as several safety concerns that have been associated with conventional solvents and extraction/purification methods.
Top Industrie will aid Medipure in achieving the Company''s goal of producing pharmaceuticals at laboratory, pilot, and commercial scales. Top Industrie has been a leader within the high pressure technology field for more than 30 years. Relying on their expert and polyvalent engineering teams and workshops, they design and build a complete range of specialized components. Each year, they develop roughly 50 turn-key systems from lab to industrial scale, including all supercritical fluid applications. They possess their own research facilities for process development, and thus are capable of providing key assistance on both process and product development. Top Industrie experts have world-class expertise in the extraction, fractionation, purification, and formulation of natural products for the pharmaceutical, nutraceutical, and ingredients industries.
Top Industrie will work closely as a collaborator/service provider with the Medipure''s R&D and Production teams to design, construct, install, and optimize the process related to advanced cannabinoid research and pharmaceutical development activities. Top Industrie will also act as a consultant for Medipure''s optimization of product preparation and development of green technology.
About Medipure Holdings Inc.
Medipure Holdings Inc. is a biopharmaceutical company focused on developing and marketing novel cannabinoid-based prescription medicines through its subsidiary, Medipure Pharmaceuticals Inc. Medipure is creating a network of strategic partnerships with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based bioactive molecules into prescription pharmaceutical products. Medipure will bring novel prescription medicines to market, providing patients with serious conditions valuable solutions that make a real difference to quality of life. Medipure will also seek to maximize the value of developed products through rapid, cost-effective product development, addressing market needs, and establishing further strategic partnerships as the company matures. Although Medipure has applied to Health Canada for a license to produce and distribute medical marihuana under the Marihuana for Medical Purposes Regulations, it has not yet received such a license and there is no guarantee that such a license will be granted to Medipure by Health Canada.
Forward-Looking Statements
Information in this press release that is not current or historical factual information may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of securities laws. This information is based on certain assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the companies cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the companies disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
This news release shall not constitute an offer to sell or the solicitation of any offer to buy the securities in any jurisdiction. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act. This press release is not intended for distribution to U.S. newswire services, and should not be disseminated within the U.S.
Contacts:
Medipure Holdings Inc.
Nathan Sellyn
Investor Relations
Medipure Holdings Inc.
Boris Weiss
Chief Executive Officer
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.05.2015 - 15:00 Uhr
Sprache: Deutsch
News-ID 1356716
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 242 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medipure Announces MOU With Top Industrie to Establish Pharmaceutical Production Platform
"
steht unter der journalistisch-redaktionellen Verantwortung von
Medipure Holdings Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
